DE60118362D1 - VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN - Google Patents
VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTINInfo
- Publication number
- DE60118362D1 DE60118362D1 DE60118362T DE60118362T DE60118362D1 DE 60118362 D1 DE60118362 D1 DE 60118362D1 DE 60118362 T DE60118362 T DE 60118362T DE 60118362 T DE60118362 T DE 60118362T DE 60118362 D1 DE60118362 D1 DE 60118362D1
- Authority
- DE
- Germany
- Prior art keywords
- present
- hemostatic
- selectin
- disorders
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/178—Lectin superfamily, e.g. selectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
- G01N2333/70564—Selectins, e.g. CD62
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20573400P | 2000-05-19 | 2000-05-19 | |
US205734P | 2000-05-19 | ||
PCT/US2001/016021 WO2001089564A2 (en) | 2000-05-19 | 2001-05-17 | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60118362D1 true DE60118362D1 (de) | 2006-05-18 |
DE60118362T2 DE60118362T2 (de) | 2007-05-24 |
Family
ID=22763420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60118362T Expired - Fee Related DE60118362T2 (de) | 2000-05-19 | 2001-05-17 | VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN |
Country Status (8)
Country | Link |
---|---|
US (4) | US20020031508A1 (de) |
EP (1) | EP1289552B1 (de) |
JP (1) | JP2003534291A (de) |
AT (1) | ATE321570T1 (de) |
AU (2) | AU6173501A (de) |
CA (1) | CA2408883A1 (de) |
DE (1) | DE60118362T2 (de) |
WO (1) | WO2001089564A2 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030198639A1 (en) | 2002-04-16 | 2003-10-23 | Frenette Paul S. | Methods of treating sickle cell disease |
US20040116333A1 (en) * | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
US7060685B2 (en) | 2002-05-16 | 2006-06-13 | Glycomimetics, Inc. | Compounds and methods for inhibiting selectin-mediated function |
CA2490703A1 (en) * | 2002-07-03 | 2004-01-15 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis |
US20040219158A1 (en) * | 2003-05-02 | 2004-11-04 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria |
TW200503734A (en) * | 2003-07-29 | 2005-02-01 | Hsin-Hou Chang | New use of soluble p-selectin and anthrax lethal toxin |
US8377887B1 (en) | 2003-07-29 | 2013-02-19 | Hsin-Hou Chang | Methods of reducing hypoxic stress in a mammal by administering soluble P-selectin |
WO2005051920A2 (en) * | 2003-11-19 | 2005-06-09 | Glycomimetics, Inc. | Specific antagonist for both e- and p-selectins |
JP2007524658A (ja) * | 2003-11-19 | 2007-08-30 | グリコミメティクス, インコーポレイテッド | E−およびp−セレクチンの両方のための糖模倣物アンタゴニスト |
MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
US8201377B2 (en) * | 2004-11-05 | 2012-06-19 | Faus Group, Inc. | Flooring system having multiple alignment points |
US7807636B1 (en) * | 2004-11-12 | 2010-10-05 | Wisconsin Alumni Research Foundation | Bovine P-selectin glycorpotein ligand-1 |
WO2006127906A1 (en) * | 2005-05-25 | 2006-11-30 | Glycomimetics, Inc. | Heterobifunctional compounds for selectin inhibition |
CA2618638C (en) * | 2005-08-09 | 2014-03-11 | Glycomimetics, Inc. | Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas |
JP5209476B2 (ja) | 2005-09-02 | 2013-06-12 | グリコミメティクス, インコーポレイテッド | ヘテロ二官能性全セレクチン阻害剤 |
US20090176717A1 (en) * | 2006-06-01 | 2009-07-09 | Glycomimetics, Inc. | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas |
EP3042668B1 (de) * | 2006-06-07 | 2018-09-19 | The Board of Trustees of the Leland Stanford Junior University | Anti-leukozyten-rekrutierungstherapie zur behandlung epileptischer anfälle |
JP5298020B2 (ja) | 2006-10-12 | 2013-09-25 | グリコミメティクス, インコーポレイテッド | ヘキソースおよびn−アセチルヘキソサミンの糖模倣体置換 |
US20100104502A1 (en) * | 2006-11-06 | 2010-04-29 | The Regents Of The University Of Michigan | Compositions and methods for detecting and treating endothelial dysfunction |
EP3501538A1 (de) | 2006-12-01 | 2019-06-26 | Novartis AG | Anti-p-selektin-antikörper und verfahren zu ihrer verwendung für die behandlung von entzündungserkrankungen |
NZ598863A (en) * | 2007-02-09 | 2013-11-29 | Glycomimetics Inc | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
US8039442B2 (en) * | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
US8895510B2 (en) | 2008-04-08 | 2014-11-25 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
CA2721093A1 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
WO2009140623A2 (en) * | 2008-05-15 | 2009-11-19 | Selexys Pharmaceuticals Corporation | Anti-psgl-1 antibodies and methods of identification and use |
WO2009152245A1 (en) * | 2008-06-13 | 2009-12-17 | Glycomimetics, Inc. | Treatment of cancers of the blood using selected glycomimetic compounds |
WO2010059315A1 (en) * | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
WO2010126888A1 (en) | 2009-05-01 | 2010-11-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
US20110150843A1 (en) * | 2009-10-30 | 2011-06-23 | National Institute Of Immunology | Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells |
AU2011237851B2 (en) * | 2010-04-08 | 2015-02-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Inhibiting peptides derived from TREM-Like Transcript 1 (TLT-1) and uses thereof |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
JP6180408B2 (ja) | 2011-06-13 | 2017-08-16 | アブゲノミクス コーペラティフ ユー.エー. | 抗psgl−1抗体およびその使用 |
ES2655443T7 (es) | 2011-12-22 | 2021-03-22 | Glycomimetics Inc | Compuestos antagonistas de E-selectina |
WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
CA2891514C (en) | 2012-12-07 | 2020-08-25 | Glycomimetics, Inc. | Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells |
US20160320416A1 (en) * | 2013-12-18 | 2016-11-03 | Siemens Healthcare Diagnostics Inc. | Detection of endothelial disease |
CN107108679B (zh) | 2014-12-03 | 2020-10-23 | 糖模拟物有限公司 | E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂 |
CA3009836A1 (en) | 2016-01-22 | 2017-07-27 | Glycomimetics, Inc. | Glycomimetic inhibitors of pa-il and pa-iil lectins |
WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
JP7069136B2 (ja) | 2016-10-07 | 2022-05-17 | グリコミメティクス, インコーポレイテッド | 極めて強力な多量体e-セレクチンアンタゴニスト |
JP7272956B2 (ja) | 2017-03-15 | 2023-05-12 | グリコミメティクス, インコーポレイテッド | E-セレクチンアンタゴニストとしてのガラクトピラノシル-シクロヘキシル誘導体 |
EP3595645A1 (de) * | 2017-03-15 | 2020-01-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmazeutische zusammensetzungen zur behandlung von thrombosen bei patienten mit einem myeloproliferativem neoplasma |
US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
CN111566117A (zh) | 2017-12-29 | 2020-08-21 | 糖模拟物有限公司 | E-选择蛋白和半乳凝素-3的异双功能抑制剂 |
WO2019165513A1 (en) * | 2018-03-02 | 2019-09-06 | Peter Gillies | A method of modulating cell proliferation |
AU2019230013A1 (en) | 2018-03-05 | 2020-09-10 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
US20190388548A1 (en) * | 2018-06-26 | 2019-12-26 | Tzu Chi University | Method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
WO2023133555A2 (en) * | 2022-01-10 | 2023-07-13 | Zilker Sciences Llc | Palmitoylethanolamide treatment for covid-19-related inflammation |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800815A (en) | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
US5605821A (en) * | 1989-03-08 | 1997-02-25 | Board Of Regents Of The University Of Oklahoma | Expression control sequences of the P-selectin gene |
US5378464A (en) * | 1989-03-08 | 1995-01-03 | Board Of Regents Of The University Of Oklahoma | Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140 |
US5026537A (en) * | 1989-04-06 | 1991-06-25 | Centocor, Inc. | Methods for imaging atherosclerotic plaque |
US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
US5807745A (en) | 1991-03-11 | 1998-09-15 | New England Medical Center Hospitals, Inc. | Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component |
AU678757B2 (en) | 1991-09-30 | 1997-06-12 | Biogen, Inc. | Inhibition of vascular narrowing using anti-padgem antibodies |
US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US6033667A (en) | 1992-05-05 | 2000-03-07 | Cytel Corporation | Method for detecting the presence of P-selectin |
US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
AU681369B2 (en) * | 1992-11-16 | 1997-08-28 | Board Of Regents Of The University Of Oklahoma, The | Glycoprotein ligand for P-selectin and methods of use thereof |
US5483707A (en) * | 1993-03-01 | 1996-01-16 | Meyer; Douglas S. | Self standing support structure and method |
CA2186108A1 (en) * | 1994-03-23 | 1995-09-28 | Scott A. Rollins | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US20020040008A1 (en) * | 1995-01-24 | 2002-04-04 | Wagner Denisa D. | Method for treating and preventing atherosclerosis |
US5763201A (en) * | 1996-02-05 | 1998-06-09 | Emory University | Flow cytometry assay for heparin-induced thrombocytopenia |
JP2001516334A (ja) * | 1996-03-01 | 2001-09-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | セレクチン結合の阻害 |
US6230713B1 (en) * | 1998-01-29 | 2001-05-15 | Margaret R. Dalesandro | Determining a treatment plan for patients undergoing thrombotic event by monitoring P-selectin |
US6596705B1 (en) * | 1998-02-09 | 2003-07-22 | The Regents Of The University Of California | Inhibition of L-selectin and P-selection mediated binding using heparin |
US6391568B1 (en) * | 1998-07-15 | 2002-05-21 | Lionheart Technologies, Inc. | Method for determining platelet reactivity in a whole blood sample |
MXPA01002898A (es) * | 1998-09-21 | 2002-06-04 | Genetics Inst | Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas. |
US6277675B1 (en) * | 1999-10-28 | 2001-08-21 | United Microelectronics Corp. | Method of fabricating high voltage MOS device |
-
2001
- 2001-05-17 AU AU6173501A patent/AU6173501A/xx active Pending
- 2001-05-17 AU AU2001261735A patent/AU2001261735B2/en not_active Ceased
- 2001-05-17 WO PCT/US2001/016021 patent/WO2001089564A2/en active IP Right Grant
- 2001-05-17 US US09/860,618 patent/US20020031508A1/en not_active Abandoned
- 2001-05-17 EP EP01935660A patent/EP1289552B1/de not_active Expired - Lifetime
- 2001-05-17 CA CA002408883A patent/CA2408883A1/en not_active Abandoned
- 2001-05-17 JP JP2001585806A patent/JP2003534291A/ja active Pending
- 2001-05-17 DE DE60118362T patent/DE60118362T2/de not_active Expired - Fee Related
- 2001-05-17 AT AT01935660T patent/ATE321570T1/de not_active IP Right Cessation
-
2004
- 2004-02-19 US US10/782,456 patent/US7387777B2/en not_active Expired - Fee Related
- 2004-11-30 US US10/999,477 patent/US20050202007A1/en not_active Abandoned
-
2008
- 2008-02-13 US US12/030,576 patent/US20080193949A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001089564A2 (en) | 2001-11-29 |
US20050202007A1 (en) | 2005-09-15 |
CA2408883A1 (en) | 2001-11-29 |
WO2001089564A3 (en) | 2002-05-10 |
US20040265311A1 (en) | 2004-12-30 |
US20080193949A1 (en) | 2008-08-14 |
US20020031508A1 (en) | 2002-03-14 |
EP1289552A2 (de) | 2003-03-12 |
EP1289552B1 (de) | 2006-03-29 |
JP2003534291A (ja) | 2003-11-18 |
AU6173501A (en) | 2001-12-03 |
ATE321570T1 (de) | 2006-04-15 |
AU2001261735B2 (en) | 2006-09-21 |
US7387777B2 (en) | 2008-06-17 |
DE60118362T2 (de) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60118362D1 (de) | VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN | |
Mei et al. | Arresting dentine caries with silver diamine fluoride: what’s behind it? | |
DE60233485D1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
ATE536855T1 (de) | Gewebegerüste zusamensetzungen zur behandlung von zahnerkrankungen | |
DE60108230D1 (de) | Vorrichtung für diagnose und behandlung von arrhytmien | |
DE69520569D1 (de) | Mittel für die behandlung von störungen des blutgerinnungsprozess | |
US6652840B1 (en) | Bleeding control and healing aid compositions and methods of use | |
DE69510336D1 (de) | Verfahren zur diagnose von praeklampsie | |
DE60042245D1 (de) | Pentamidine zur behandlung von krebs | |
ATE338142T1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
DE602004011400D1 (de) | Behandlung von neurodegenerative krankheiten mit gpr49 | |
DE602004026683D1 (de) | Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins | |
DE69920844D1 (de) | Fäulnisverhinderndes mittel, verfahren zur fäulnisverhindernden behandlung und durch diese behandlung erhaltener gegenstand | |
Bayoumi et al. | The effects of using hyaluronic acid on the extraction sockets | |
DE60042171D1 (de) | Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen | |
DE69302276T2 (de) | Diagnostische Methode | |
WO2003065871A3 (en) | Methods and compositions for treating hematological disorders | |
ATE390435T1 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie | |
ATA187398A (de) | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen | |
ATE240352T1 (de) | Komplexverbindungen zur diagnose von gefässerkrankungen | |
DE69928814D1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
ATE554790T1 (de) | Verfahren und zusammensetzungen zur diagnose von asthma | |
ATE397090T1 (de) | Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen | |
ATE376425T1 (de) | Verfahren zur behandlung bestimmter augenkrankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de | ||
8370 | Indication related to discontinuation of the patent is to be deleted | ||
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |